MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events Data from the Phase 2b RESTORE trial.
Nanoscope Therapeutics Announces Positive Top-Line Results From Randomized Controlled Trial Of MCO-010 For Retinitis Pigmentosa menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.